Antidepressant efficacy and tolerability of the selective norepinephrine reuptake inhibitor reboxetine: a review.

作者: Graham D. Burrows , Kay P. Maguire , Trevor R. Norman

DOI:

关键词: PsychologyAntidepressantReuptake inhibitorTolerabilityReboxetineHamilton Rating Scale for DepressionAdverse effectInternal medicineMajor depressive disorderAnesthesiaClinical trial

摘要: Reboxetine is a unique selective norepinephrine reuptake inhibitor (NRI) with proven antidepressant efficacy in pharmacologic and biochemical tests predictive of properties. Comprehensive clinical trials, including 8 placebo-controlled and/or active treatment-controlled studies, plus 4 open have assessed the short-term long-term tolerability reboxetine patients major depressive disorders dysthymia. Results from total 690 who entered 5 or studies are summarized this paper. Four hundred forty-nine diagnosis either disorder dysthymia were treated these weeks' to 12 months' duration. In 6-week study, clinically significant improvement (≥ 50% reduction Hamilton Rating Scale for Depression score) was observed at last assessment 74% reboxetine-treated compared 20% placebo group. Similar results run-in phases 3 where maintained over 12-month study period. well tolerated; adverse events reported mainly mild moderate severity, there no changes vital signs laboratory parameters. The first its class, reboxetine, NRI, will provide valuable addition existing armamentarium agents used treatment depression.

参考文章(0)